"Blast Crisis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.
| Descriptor ID |
D001752
|
| MeSH Number(s) |
C04.557.337.539.250.100 C04.697.098.500.110 C15.378.190.636.370.100 C23.550.727.098.500.110
|
| Concept/Terms |
Blast Crisis- Blast Crisis
- Blast Crises
- Crises, Blast
- Crisis, Blast
- Blast Phase
- Blast Phases
- Phase, Blast
- Phases, Blast
|
Below are MeSH descriptors whose meaning is more general than "Blast Crisis".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Leukemia [C04.557.337]
- Leukemia, Myeloid [C04.557.337.539]
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C04.557.337.539.250]
- Blast Crisis [C04.557.337.539.250.100]
- Neoplastic Processes [C04.697]
- Carcinogenesis [C04.697.098]
- Cell Transformation, Neoplastic [C04.697.098.500]
- Blast Crisis [C04.697.098.500.110]
- Hemic and Lymphatic Diseases [C15]
- Hematologic Diseases [C15.378]
- Bone Marrow Diseases [C15.378.190]
- Myeloproliferative Disorders [C15.378.190.636]
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C15.378.190.636.370]
- Blast Crisis [C15.378.190.636.370.100]
- Pathological Conditions, Signs and Symptoms [C23]
- Pathologic Processes [C23.550]
- Neoplastic Processes [C23.550.727]
- Carcinogenesis [C23.550.727.098]
- Cell Transformation, Neoplastic [C23.550.727.098.500]
- Blast Crisis [C23.550.727.098.500.110]
Below are MeSH descriptors whose meaning is more specific than "Blast Crisis".
This graph shows the total number of publications written about "Blast Crisis" by people in this website by year, and whether "Blast Crisis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Blast Crisis" by people in Profiles.
-
An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemia. Nat Cancer. 2020 04; 1(4):410-422.
-
Optic neuropathy in extramedullary, blast crisis of chronic myeloid leukemia. Can J Ophthalmol. 2019 06; 54(3):e128-e131.
-
Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia. 2017 03; 31(3):585-592.
-
Disseminated blastic plasmacytoid dendritic cell neoplasm. Blood. 2015 Jul 23; 126(4):558.
-
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer. 2014 Feb 01; 120(3):373-80.
-
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leuk Res. 2012 Dec; 36(12):1500-4.
-
Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma. 2013 Jan; 54(1):138-44.
-
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51.
-
Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment. Cancer. 2012 Nov 01; 118(21):5283-92.
-
Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia. 2012 Apr; 26(4):788-94.